Prof. Bing Xiu | Hematology | Best Researcher Award

Prof. Bing Xiu | Tongji University | China 

Prof. Bing Xiu is an esteemed Associate Chief Physician and Vice Professor at the Department of Hematology, Tongji Hospital, Tongji University, Shanghai, China. With over two decades of experience in hematology, she holds a Ph.D. in Internal Medicine and has undertaken advanced training at the Mayo Clinic, USA. Prof. Xiu is a certified specialist in internal medicine and hematology and serves as a Master’s supervisor. Her research focuses on lymphoma, T-cell exhaustion, immunotherapy, and CAR-T related cytokine release syndrome. She has led and contributed to several major national and international research projects, including those funded by the NSFC and NIH. Prof. Xiu has published extensively in high-impact journals like Blood Cancer Journal, Leukemia, and Clinical Cancer Research, and has presented at ASH and ASCO, earning abstract honors. She also co-edited a clinical dataset book on diffuse large B-cell lymphoma and is active in several national medical associations and academic committees.

Publication Profile

Scopus

Education Background

Prof. Bing Xiu has pursued her entire medical education at the prestigious Medical College of Tongji University in Shanghai, China, demonstrating a consistent commitment to academic excellence and specialization in internal medicine. She began her journey in medicine by earning her Bachelor of Medicine degree from Tongji University, where she laid the foundational knowledge in clinical sciences. Her passion for hematology and internal medicine led her to further academic pursuit, completing her Master of Medicine from the same institution. With an increasing focus on clinical research and advanced therapeutics, Prof. Xiu earned her Ph.D. in Internal Medicine from Tongji University, focusing on cutting-edge areas of hematologic malignancies. This continuous and progressive educational pathway has equipped her with deep theoretical knowledge and advanced research capabilities that have significantly influenced her medical and academic career.

Professional Experience

Prof. Bing Xiu has built a distinguished career in hematology through extensive clinical, academic, and international experience. She serves as the Associate Chief Physician in the Department of Hematology at Tongji Hospital, Tongji University, Shanghai, where she also holds the role of Master’s supervisor. Her international exposure includes prestigious appointments as a Research Fellow and Visiting Clinician at the Mayo Clinic, Rochester, USA. Prof. Xiu’s earlier roles at Tongji Hospital include her tenure as a Fellow and as a Resident, marking a steady progression in her professional responsibilities. This rich blend of domestic and international clinical research and patient care has shaped her into a leader in hematology and academic mentorship.

Professional Certifications

Prof. Bing Xiu holds esteemed certifications that underscore her clinical expertise and professional standing in the field of internal medicine and hematology. She is certified by the Chinese Board of Internal Medicine, which affirms her comprehensive proficiency in diagnosing and managing a wide range of medical conditions. In addition, she possesses a specialized certification in Internal Medicine-Hematology from the same board, highlighting her focused expertise in the diagnosis and treatment of blood disorders, hematologic malignancies, and related immunological conditions. These dual certifications not only reflect her advanced clinical training but also qualify her to deliver high-level patient care, contribute to academic leadership, and mentor postgraduate students in hematology. Recognized by national regulatory authorities, these credentials form the foundation of her credibility and professionalism in China’s medical and academic community, supporting her roles in major research projects, teaching, and leadership in national medical societies.

Research Focus

Prof. Bing Xiu focuses her research on the molecular and translational mechanisms underlying hematologic malignancies, with particular emphasis on lymphomas and myeloproliferative neoplasms. Her recent publications explore critical areas such as germline mutations in lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH), indicating an interest in immune dysregulation and genetic predisposition in aggressive B-cell lymphomas. She has also investigated epigenetic and genetic alterations, such as single nucleotide polymorphisms and promoter methylation of protein tyrosine phosphatase 1B, in myeloproliferative disorders, showcasing her engagement in cancer genomics. Furthermore, her research integrates cutting-edge immunotherapies, including CAR T-cell therapy combined with autologous hematopoietic cell transplantation for refractory/relapsed Burkitt lymphoma, indicating her commitment to improving outcomes through personalized and cellular therapies. Collectively, her work lies at the intersection of cancer genetics, immunotherapy, and translational hematology, making significant contributions to advancing targeted and immune-based treatments for hematologic cancers.

Publication Top Notes

1. Germline mutations in B-cell non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH) and patient outcomes
Publication Year: 2025

2. Single nucleotide polymorphism and promoter methylation analysis of protein tyrosine phosphatase 1B in patients with myeloproliferative neoplasms
Publication Year: 2025

3. CAR T-cell therapy combined with autologous hematopoietic cell transplantation in patients with refractory/relapsed Burkitt Lymphoma
Publication Year: 2025
Citations: 1

Conclusion

Prof. Bing Xiu is highly suitable for the Best Researcher Award. Her record combines clinical excellence, high-impact hematological research (particularly in lymphoma and immunotherapy), international collaboration, grant leadership, and academic publishing. With a few more translational innovations or expanded global leadership, she would stand at the pinnacle of international medical research. As it stands, she is a top-tier candidate whose body of work exemplifies the award’s purpose to honor groundbreaking research with societal and scientific relevance.